Video

Dr. Dalton on Toxicities in the Frontline Treatment of Ovarian Cancer

Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses toxicities in the frontline treatment of patients with ovarian cancer.

Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses toxicities in the frontline treatment of patients with ovarian cancer.

Both PARP inhibitors and immunotherapy have been bursting onto the scene in ovarian cancer, most recently in the frontline setting. With the introduction of these new therapies comes class-specific toxicities that are beginning to be understood.

With PARP inhibitors, there are hematologic events and gastrointestinal toxicities. Dalton says that physicians are getting better about adjusting the dosing of PARP inhibitors when these toxicities arise. For checkpoint inhibitors, there are common but sometimes serious immune-related adverse events such as pneumonitis that need to be tended to. As time goes on, Dalton says that these toxicities will be able to be managed more effectively.

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD